Northwest Biotherapeutics Inc (NWBO) Stock Price & Analysis
Northwest Biotherapeutics Inc (NWBO) fell 3.08% to USD 0.19 as of June 10, 2026 at 05:53 UTC, according to Nexqual real-time market data.
NWBO last closed at USD 0.2; the session ranged USD 0.19–0.2 on volume of 936,504 shares. Market capitalization is $315.52M, with a 52-week range of USD 0.18–0.37 (OQB). Source: Nexqual, June 10, 2026 at 05:53 UTC.
Key Statistics (as of June 10, 2026 at 05:53 UTC)
| Price | USD 0.19 |
|---|---|
| Change | ▼ 3.08% (down) |
| Previous Close | USD 0.2 |
| Open | USD 0.2 |
| Day Range | USD 0.19 – 0.2 |
| 52-Week Range | USD 0.18 – 0.37 |
| Volume | 936,504 shares |
| Market Cap | $315.52M |
| Exchange | OQB |
Technical Analysis (NWBO)
Nexqual's technical model rates NWBO "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 05:53 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.43 (neutral) |
| vs SMA50 | Below (USD 0.21) |
| MACD | -0 (negative) |
Analyst Ratings (NWBO)
Wall Street analysts rate NWBO "Buy" based on 1 analysts, with a mean price target of USD 1 (range USD 1–1), per Nexqual as of June 10, 2026 at 05:53 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 1 |
| High Target | USD 1 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (NWBO)
| Next Earnings Date | 2026-08-13 |
|---|
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Financials & Fundamentals (NWBO)
| Total Revenue | $1.50M |
|---|---|
| Revenue Growth (YoY) | +31.70% |
| Gross Margin | +0.00% |
| Operating Margin | -2206.48% |
| Profit Margin | +0.00% |
| Current Ratio | 0.08 |
| Total Cash | $1.79M |
| Total Debt | $63.99M |
| Free Cash Flow | $-36.92M |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Financial Health Score (NWBO)
Nexqual rates Northwest Biotherapeutics Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 05:53 UTC.
| Growth | Strong — Revenue +32% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $2M cash vs $64M debt |
| Cash Flow | Weak — Operating cash flow -$48M |
| Efficiency | Mixed — No data |
Ownership (NWBO)
| Insider Ownership | +4.26% |
|---|---|
| Institutional Ownership | +0.06% |
| Shares Outstanding | 1.64B |
| Float | 1.61B |
| Short % of Float | +15.09% |
Source: Nexqual, June 10, 2026 at 05:53 UTC.
Leadership (NWBO)
Northwest Biotherapeutics Inc is led by Linda F. Powers (age 69), Chairperson, CEO, President, CFO & Chief Accounting Officer, per Nexqual as of June 10, 2026 at 05:53 UTC.
| Chairperson, CEO, President, CFO & Chief Accounting Officer | Linda F. Powers (age 69) |
|---|---|
| Founder, Chief Scientific Officer, Secretary & Director | Alton L. Boynton (age 80) |
| Vice President of Investor Relations | David Innes |
From Northwest Biotherapeutics Inc's Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer.
- The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
- It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer.
- In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IMUC | EOM Pharmaceutical Holdings Inc | USD 0.25 | ▲ 17.92% |
| CLDX | Celldex Therapeutics, Inc. | USD 29.6 | ▲ 3.42% |
| CVM | Cel-Sci Corporation | USD 1.3 | ▼ 5.11% |
| ATNM | Actinium Pharmaceuticals, Inc. | USD 1.01 | ▼ 6.48% |
| AGEN | Agenus Inc. | USD 3.11 | ▼ 3.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:53 UTC. This page is informational and not investment advice.